{"id":"W2587075560","doi":"10.1182/blood.v104.11.3278.3278","title":"Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; University of Alberta Hospital; Alberta Hospital Edmonton; Juravinski Cancer Centre; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Rituximab; Waldenstrom macroglobulinemia; Gastroenterology; Macroglobulinemia; Lenalidomide; Chlorambucil; Fludarabine; Cladribine; Thalidomide; Multiple myeloma; Regimen; Lymphoplasmacytic Lymphoma; Chemotherapy; Lymphoma; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002045019,0.0003124442,0.0009588987,0.0002972132,0.00005412157,0.000008520173,0.0002101192,0.0001361668,0.00008823803],"category_scores_gemma":[0.0002105967,0.0002177256,0.00007679702,0.001028664,0.0001738052,0.000108587,0.0001282039,0.0002887785,0.000005206599],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002125881,"about_ca_system_score_gemma":0.004114749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005976298,"about_ca_topic_score_gemma":0.001517538,"domain_scores_codex":[0.9973847,0.00009239837,0.0006411462,0.0005133556,0.0008250767,0.0005433462],"domain_scores_gemma":[0.9984114,0.00007350957,0.00029594,0.0006831742,0.0003243415,0.0002116475],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.05587493,0.2934973,0.5995057,0.00165833,0.002279628,0.00589817,0.007521955,0.0001722498,0.02510711,0.000008833418,0.00008024413,0.008395541],"study_design_scores_gemma":[0.6335111,0.0379272,0.1985468,0.0009062793,0.001048584,0.0001512896,0.0003440686,0.0001772972,0.1270527,0.00000336721,0.00001332484,0.0003180933],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969088,0.00006183572,0.000003422457,0.00003058681,0.00001749833,0.002717885,0.0000799036,0.0000530086,0.0001270627],"genre_scores_gemma":[0.9994085,0.00002349215,0.0001899616,0.00001092241,0.00002761185,0.00006377679,0.0000595918,0.00004898617,0.0001671569],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5776361,"threshold_uncertainty_score":0.9034415,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01537208609548834,"score_gpt":0.301797900612425,"score_spread":0.2864258145169367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}